NCT02420860 2026-04-15
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04835129 2026-03-27
IMPEDE
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT02718833 2026-01-22
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04517851 2026-01-13
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05560399 2026-01-02
CC-220
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Active not recruiting
NCT05028348 2025-12-04
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03989414 2024-11-29
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
Phase 1/2 Active not recruiting
NCT03948035 2023-05-06
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Wuerzburg University Hospital
Phase 3 Active not recruiting
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting